Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

• By Mandy Jackson

Risk versus value matrix with pushpins and blur effect. Concept of investment risk assessment.

Related Content

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Sep 12 2018

Celgene Eyes IO Growth With BeiGene China Pact

Jul 06 2017

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Jan 04 2019

'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

Dec 03 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

Bristol/Celgene A Record-Setting Merger, If It Happens

Jan 04 2019

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

Jun 06 2018

Celgene diversifies with $7.2bn Receptos buy

Jul 15 2015

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Jan 09 2018

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Oct 25 2018

Celgene's Focus On Execution Pays Off, But Follow-Through Is Key

Oct 25 2018

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Oct 20 2017

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Natco Pharma Limited

Merck & Co., Inc.

Receptos, Inc.

Impact Biomedicines, Inc.

BeOne Medicines Ltd.

Acceleron Pharma, Inc.

Bristol Myers Squibb Company

Genetix Biotherapeutics

Sanofi

Additional Topics

M & A Business Strategies Deals ImmunoOncology Companies Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window